慢性病中的尿素II系统
Olugbenga S Michael1,2, Praghalathan Kanthakumar1,2, Hitesh Soni2
1Department of Medical Pharmacology and Physiology, University of Missouri, Columbia, MO, USA.
Current research in physiology
|May 23, 2024
概括
尿素II (UII) 系统,涉及UII及其受体UT,在慢性病 (CKD) 进展中发挥作用. 针对这个系统可能会为治疗慢性脏病提供新的治疗策略.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
- 心血管研究研究心血管研究
背景情况:
- 慢性病 (CKD) 影响全球人口的10%以上,是致病率和死亡率的主要原因.
- 慢性脏病经常与糖尿病,高血压和丸炎有关,这凸显了对新型治疗点的需求.
- 尿素II (UII) 系统,包括UII,UII相关 (URP) 和UT受体,与心血管和功能障碍有关.
研究的目的:
- 审查尿素II (UII) 系统与慢性病 (CKD) 之间的不断变化的联系.
- 在CKD病理生理学中探索潜在的机制,治疗含义,争议和与UII系统相关的未经探索的概念.
- 了解脏和外器官中UII系统的细胞机制,以了解其在CKD中的作用.
主要方法:
- 对研究尿素II (UII) 系统及其与慢性病 (CKD) 的关联的文献综述.
- 对UII和UII相关 (URP) 表达水平及其与脏和心血管疾病的联系的研究分析.
- 检查动物脏和心血管疾病模型中UT受体的药理抑制或遗传移除的临床前数据.
主要成果:
- 尿路和尿路表达和尿路度的变化与高血压,心力衰竭,血球炎和糖尿病有关.
- UII基因多态性与患糖尿病的风险增加有关.
- 在动物模型中,UT的药理抑制或遗传切除已经显示出减轻脏和心血管疾病的前景.
结论:
- 尿素II (UII) 系统是减缓慢性病 (CKD) 进展的潜在治疗标.
- 进一步研究各种器官中UII系统的细胞机制对于开发有效的CKD疗法至关重要.
- 了解UI系统的作用对于推进CKD管理和改善患者的治疗结果至关重要.
相关概念视频
01:13Introduction to Urinary System
2.5K
The urinary system consists of two kidneys, two ureters, the urinary bladder, and the urethra.
The kidneys are bean-shaped organs located in the retroperitoneal space, on either side of the vertebral column, between the T12 and L3 vertebrae. They are partially protected by the rib cage and surrounded by perirenal fat, which provides cushioning. They are responsible for urine formation and play critical roles in regulating blood pressure, electrolyte levels, and hormone production. The ureters...
The kidneys are bean-shaped organs located in the retroperitoneal space, on either side of the vertebral column, between the T12 and L3 vertebrae. They are partially protected by the rib cage and surrounded by perirenal fat, which provides cushioning. They are responsible for urine formation and play critical roles in regulating blood pressure, electrolyte levels, and hormone production. The ureters...
2.5K
01:33Hormonal Regulation
33.1K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
33.1K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
597
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
597
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
618
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
618
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
714
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
714
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
421
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421